A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Topiramate, an anticonvulsant medication, is an efficacious treatment for alcohol dependence. To date, little is known about genetic moderators of side effects from topiramate. The objective of this study was to examine 3 single nucleotide polymorphisms (SNPs) of the glutamate receptor GluR5 gene (GRIK1) as predictors of topiramate-induced side effects in the context of a laboratory study of topiramate. Heavy drinkers (n=51, 19 women and 32 men), 75% of whom met criteria for an alcohol use disorder, completed a 5-week dose escalation schedule to a target dose of either 200 or 300 mg or matched placebo. The combined medication groups were compared with placebo-treated individuals for side effects at target dose. Analyses revealed that an SNP in intron 9 of the GRIK1 gene (rs2832407) was associated with the severity of topiramate-induced side effects and with serum levels of topiramate. Genes underlying glutamatergic neurotransmission, such as the GRIK1 gene, may help predict heterogeneity in topiramate-induced side effects. Future studies in larger samples are needed to more fully establish these preliminary findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571 · cited 1×
“This SNP has been found to predict more favorable responses to naltrexone in the laboratory (Ray & Hutchison, 2007) and in clinical trials (Anton et al., 2008; Oslin et al., 2003).”
BackgroundTopiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · cited 1×
“This SNP has been found to predict more favorable responses to naltrexone in the laboratory (Ray & Hutchison, 2007) and in clinical trials (Anton et al., 2008; Oslin et al., 2003).”
BackgroundSelf-citationRay, L. A., & Hutchison, K. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1069 · Cited by 258 · cited 1×
“This SNP has been found to predict more favorable responses to naltrexone in the laboratory (Ray & Hutchison, 2007) and in clinical trials (Anton et al., 2008; Oslin et al., 2003).”
BackgroundSelf-citation
Cited by
Pharmacological approaches to reducing craving in patients with alcohol use disorders
Haass-Koffler, C. L., Leggio, L., & Kenna, G. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0149-3 · Cited by 83
“A pharmacogenetic investigation also reported that a SNP (rs2832407) of the GRIK1 (glutamate receptor, ionotropic, kainite 1) gene was associated with serum levels of topiramate, affecting the severity of topiramate-induced side effects on the basis of genotype [174].”
Nourredine, M., Jurek, L., Angerville, B., Longuet, Y., de Ternay, J., Derveaux, A., & Rolland, B. (2021) · CNS Drugs · doi:10.1007/s40263-020-00780-y · Cited by 26
“Furthermore, the pharmacogenetic profile appeared to influence the efficacy of topiramate according to a preliminary laboratory study [101] and to an RCT [21] and an unblinded follow-up trial [30].”
BackgroundGray, J. C., Treloar Padovano, H., Wemm, S. E., & Miranda, R. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000843 · Cited by 18
Self-citation
Metadata
- Authors
- Ray, L. A., Miranda, R., MacKillop, J., McGeary, J., Tidey, J. W., Rohsenow, D. J., Gwaltney, C., Swift, R. W., & Monti, P. M.
- Venue
- Experimental and Clinical Psychopharmacology
- Published
- 2009-04
- Volume
- 17
- Issue
- 2
- Pages
- 122-129
- ISSN
- 1064-1297 (ISSN-L)
- 1936-2293
- OpenAlex
- W2064832878
- Cited by
- 69
- References
- 5
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. https://app.cochat.ai/papers/10.1037/a0015700
- The paper
- Ray, L. A., Miranda, R., MacKillop, J., McGeary, J., Tidey, J. W., Rohsenow, D. J., Gwaltney, C., Swift, R. W., & Monti, P. M. (2009). A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037/a0015700
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.